Informação da revista
Vol. 31. Núm. 7 - 8.
Páginas 529-538 (Julho - Agosto 2012)
Partilhar
Partilhar
Baixar PDF
Mais opções do artigo
Vol. 31. Núm. 7 - 8.
Páginas 529-538 (Julho - Agosto 2012)
Editor's network
Open Access
Relations between professional medical associations and healthcare industry, concerning scientific communication and continuing medical education: a Policy Statement from the European Society of Cardiology
Visitas
8462
ESC Board
Autor para correspondência
faustopin@gmail.com

Corresponding author.
Este item recebeu

Under a Creative Commons license
Informação do artigo
Resume
Texto Completo
Bibliografia
Baixar PDF
Estatísticas

Physicians have an ethical duty to keep up-to-date with current knowledge. Professional medical associations such as the European Society of Cardiology (ESC) support these obligations. In Europe, the costs of continuing medical education (CME) are insufficiently supported from governments and employers; however, medical associations have been criticized for accepting alternative financial support from industry. Medical education and training in research include learning how to assess the quality and reliability of any information. There is some risk of bias in any form of scientific communication including intellectual, professional, and financial and it is essential that in particular, the latter must be acknowledged by full disclosure. It is essential that there is strong collaboration between basic and clinical researchers from academic institutions on the one hand, with engineers and scientists from the research divisions of device and pharmaceutical companies on the other. This is vital so that new diagnostic methods and treatments are developed. Promotion of advances by industry may accelerate their implementation into clinical practice. Universities now frequently exhort their academic staff to protect their intellectual property or commercialize their research. Thus, it is not commercial activity or links per se that have become the target for criticism but the perceived influence of commercial enterprises on clinical decision-making or on messages conveyed by professional medical organizations. This document offers the perspective of the ESC on the current debate, and it recommends how to minimize bias in scientific communications and CME and how to ensure proper ethical standards and transparency in relations between the medical profession and industry.

Keywords:
Scientific communications
CME
O texto completo está disponível em PDF
References
[1]
N.K. Choudhry, H.T. Stelfox, A.S. Detsky.
Relationships between authors of clinical practice guidelines and the pharmaceutical industry.
JAMA, 287 (2002), pp. 612-617
[2]
M.D. Jibson.
Medical education and the pharmaceutical industry: managing an uneasy alliance.
Acad Psychiatry, 30 (2006), pp. 36-39
[3]
R. Moynihan.
Doctors’ education: the invisible influence of drug company sponsorship.
[4]
S.H. Podolsky, J.A. Greene.
A historical perspective of pharmaceutical promotion and physician education.
JAMA, 300 (2008), pp. 831-833
[5]
Lo B, Field MJ, eds. Conflict of Interest in Medical Research, Education, and Practice. Washington: Institute of Medicine; 2009. ISBN: 978-0-309-13188-9.
[6]
EFPIA. EFPIA code on the promotion of prescription-only medicines to, and interactions with, healthcare professionals, 2007. www.efpia.eu/Content/Default. asp?PageID=559&DocID=3483.(20 January 2012).
[7]
FPMA. IFPMA Code of Pharmaceutical Marketing Practices 2006 Revision. Appendix 1. 2006. www.ifpma.org/fileadmin/templates/EthicalPromotion/pdfs/IFPMA-TheCodeOperatingProcedure-2006.pdf.
[8]
ABPI. Code of practice for the pharmaceutical industry, 2006. www.abpi.org.uk/links/assoc/PMCPA/pmpca_code2006.pdf.
[9]
Organisation for Economic Co-operation and Development. Recommendation for Further Combating Bribery of Foreign Public Officials in International Business Transactions. Paris, France: OECD; 2009. http://www.oecd.org/document/20/0,3343,en_2649_34859_2017813_1_1_1_1,00.html. (20 January 2012).
[10]
Hager M, Russell S, Fletcher SW, eds. Continuing education in the health professions: improving healthcare through lifelong learning. Proceedings of a conference sponsored by the Josiah Macy, Jr. Foundation. New York, 2008. ISBN 0-914362-49-6. www.josiahmacyfoundation.org.(20 January 2012).
[11]
P.E. Mazmanian.
Commercial support of continuing medical education in the United States: the politics of doubt, the value of studies.
J Contin Educ Health Prof, 29 (2009), pp. 81-83
[12]
S. Chimonas, D.J. Rothman.
New federal guidelines for physician-pharmaceutical industry relations: the politics of policy formation.
Health Aff (Millwood), 24 (2005), pp. 949-960
[13]
D.J. Rothman, W.J. McDonald, C.D. Berkowitz, S.C. Chimonas, C.D. DeAngelis, R.W. Hale, S.E. Nissen, J.E. Osborn, J.H. Scully Jr., G.E. Thomson, D. Wofsy.
Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest.
JAMA, 301 (2009), pp. 1367-1372
[14]
M.M. Chren, C.S. Landefeld.
Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary.
JAMA, 271 (1994), pp. 684-689
[15]
A. Wazana.
Physicians and the pharmaceutical industry: is a gift ever just a gift?.
JAMA, 283 (2000), pp. 373-380
[16]
R.C. Hatton, M.L. Chavez, E. Jackson, J. Maurey, S.L. Barriere, R. Couchenour, R.P. Evens, K. Gunning, A.L. Hume, L.C. Hutchison, G.R. Matzke, J.A. Noviasky, R.M. Rospond, J.S. Kelloway, J.G. Stevenson, R.P. Vanderveen, C.N. Verme-Gibboney, D. Walters.
Pharmacists and industry: guidelines for ethical interactions.
Pharmacotherapy, 28 (2008), pp. 410-420
[17]
K. Dickersin.
The existence of publication bias and risk factors for its occurrence.
JAMA, 263 (1990), pp. 1385-1389
[18]
H.T. Stelfox, G. Chua, K. O’Rourke, A.S. Detsky.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med, 338 (1998), pp. 101-106
[19]
M. Friedberg, B. Saffran, T.J. Stinson, W. Nelson, C.L. Bennett.
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
JAMA, 282 (1999), pp. 1453-1457
[20]
J.S. Ross, K.P. Hill, D.S. Egilman, H.M. Krumholz.
Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.
JAMA, 299 (2008), pp. 1800-1812
[21]
E.D. Pellegrino, A.S. Relman.
Professional medical associations: ethical and practical guidelines.
JAMA, 282 (1999), pp. 984-986
[22]
J.S. Ross, G. Coutts, R. Tiner, M. Angell, S. Gottlieb.
Doctors, patients and the drug industry: partners, friends, or foes?.
BMJ, 338 (2009), pp. 326-329
[23]
R.A. Harrington, R.M. Califf.
There is a role for industry-sponsored education in cardiology.
Circulation, 121 (2010), pp. 2221-2227
[24]
R.H. Gelberman, D. Samson, S.K. Mirza, J.J. Callaghan, V.D. Pellegrini.
Orthopaedic surgeons and the medical device industry: the threat to scientific integrity and the public trust.
J Bone Joint Surg Am, 92 (2010), pp. 765-777
[25]
O. Bruyere, J.A. Kanis, M.E. Ibar-Abadie, N. Alsayed, M.L. Brandi, N. Burlet, D.L. Cahall, A. Chines, J.P. Devogelaer, W. Dere, N. Goel, N. Hughes, J.M. Kaufman, S. Korte, B.H. Mitlak, D. Niese, R. Rizzoli, L.C. Rovati, J.Y. Reginster.
The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES).
Osteoporos Int, 21 (2010), pp. 713-722
[26]
J.M. Drazen, G.D. Curfman.
Financial associations of authors.
N Engl J Med, 346 (2002), pp. 1901-1902
[27]
J. Lexchin, O. O’Donovan.
Prohibiting or ‘managing’ conflict of interest?. A review of policies and procedures in three European drug regulation agencies.
Soc Sci Med, 70 (2010), pp. 643-647
[28]
Association of American Medical Colleges. Industry Funding of Medical Education. Report of an AAMC Task Force. Washington, DC: AAMC; 2008. http://services.aamc.org/publications/showfile.cfm?file=version114.pdf.
[29]
European Commission, SEC(2010) 1161. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions. Europe 2020 Flagship Initiative. Innovation Union. Brussels, 6.1.2010. http://ec.europa.eu/research/innovation-union/pdf/innovation unioncommunication_en.pdf.
[30]
S. Merkur, E. Mossialos, M. Long, M. McKee.
Physician revalidation in Europe.
Clin Med, 8 (2008), pp. 371-376
[31]
H. Maisonneuve, Y. Matillon, A. Negri, L. Pallares, R. Vigneri, H.L. Young.
Continuing medical education and professional revalidation in Europe: five case examples.
J Contin Educ Health Prof, 29 (2009), pp. 58-62
[32]
Fras Z, Destrebecq F, Creplet C, Welling C. Survey of European CME/CPD. Continuing Medical Education and Professional Development. Brussels: European Union of Medicine Specialists (UEMS); 2008. http://www.uems.net/ (20 January 2012).
[33]
L. Garattini, S. Gritti, P. De Compadri, G. Casadei.
Continuing medical education in six European countries: a comparative analysis.
Health Policy, 94 (2010), pp. 246-254
[34]
Desbois EJ, Pardell H, Negri A, Kellner T, Posel P, Kleinoeder T, Maillet B, Maisonneuve H. Continuing medical education in Europe: evolution or revolution, 2010. http://www .continuingmedicaleducation-europe.com/ (20 January 2012).
[35]
Organisme Gestionnaire Conventionnel. Rapport d’activite¿ FPC (Formation professionnelle conventionnelle) 2009;10-11.
[36]
Royal College of Physicians. (RCP). Innovating for health: patient, physicians, the pharmaceutical industry and the NHS. Report of a Working Party, 2009. http://www.rcplondon.ac.uk/pubs/contents/76673804-76c5-4ab3-89a0-92d44e45edc3.pdf.
[37]
Netherlands Federation of University Medical Centres. Collective agreement for University Medical Centres, 1 January 2008-1 March 2011. NFU-083083, article 15.9.1. http://www.nfu.nl/fileadmin/documents/Werkg-NFU20083083-OFF-ENG-CAOv081016.pdf.
[38]
Accreditation Council for Continuing Medical Education (ACCME). Annual Report Data 2008. http://www.accme.org/dir_docs/doc_upload/1f8dc476-246a-4e8e-91d3d24ff2f5bfec_uploaddocument.pdf.
[39]
American Heart Association. AHA annual report 2009. http://www.nxtbook.com/tristar/tristar/aha_annualreport09/index.php#/30 (20 January 2012).
[40]
Camilleri M, Parke DW 2nd. Perspective: conflict of interest and professional organizations: considerations and recommendations. Acad Med 2010;85: 85-91.
[41]
Criteria for international accreditation of CME. European Union of Medical Specialists, 2007. http://admin.uems.net/uploadedfiles/1411.pdf.
[42]
Fletcher S. Pharma and CME: view from the US. BMJ 2008; 337:a1023.
[43]
D.A. Davis, M.A. Thompson, A.D. Oxman, B. Haynes.
Changing physician performance: a systematic review of the effect of continuing medical education strategies.
JAMA, 274 (1995), pp. 700-705
[44]
D. Davis, M.A.T. O’Brien, N. Freemantle, F.M. Wolf, P. Mazmanian, A. Taylor-Vaisey.
Impact of formal continuing medical education Do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes?.
JAMA, 282 (1999), pp. 867-874
[45]
L. Bowen Judith.
Medical education: educational strategies to promote clinical diagnostic reasoning.
N Engl J Med, 355 (2006), pp. 2217-2225
[46]
Kahn N. Industry support and professional medical associations—letter to the editor. JAMA 2009;302:737.
[47]
Smith CD, Buyske J, Talamini MA. Industry support and professional medical associations—letter to the editor. JAMA 2009;302:738-739.
[48]
S.L. Coyle, relations. Physician-industry.
Part 1: individual physicians.
Ann Intern Med, 136 (2002), pp. 396-402
[49]
S.L. Coyle, relations. Physician-industry.
Part 2: organizational issues.
Ann Intern Med, 136 (2002), pp. 403-406
[50]
European Medicines Agency (EMA). Policy on the Handling of Conflicts of Interests of Management Board and Scientific Committee Members and EMEA Experts. London: EMA; 2006. http://www.ema.europa.eu/pdfs/general/direct/conflicts/3165303en.pdf.
[51]
E.A. Boyd, L.A. Bero.
Improving the use of research evidence in guideline development: 4. Managing conflicts of interest.
Health Res Policy Syst, 4 (2006), pp. 16
[52]
G. Guyatt, E.A. Akl, J. Hirsh, C. Kearon, M. Crowther, D. Gutterman, S.Z. Lewis, I. Nathanson, R. Jaeschke.
Schu¿nemann H. The vexing problem of guidelines and conflict of interest: a potential solution.
[53]
P.B. Mitchell.
Winds of change: growing demands for transparency in the relationship between doctors and the pharmaceutical industry.
Med J Aust, 191 (2009), pp. 273-275
[54]
H.J. Schu¿nemann, M. Osborne, J. Moss, C. Manthous, G. Wagner, L. Sicilian, J. Ohar, S. McDermott, L. Lucas, R. Jaeschke.
ATS Ethics and Conflict of Interest Committee and the Documents Development and Implementation Committee An official American Thoracic Society Policy statement: managing conflict of interest in professional societies.
Am J Respir Crit Care Med, 180 (2009), pp. 564-580
[55]
International Committee of Medical Journal Editors. Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest. ICMJE; 2009. http://www. icmje.org/ethical_4conflicts.html (20 January 2012).

Secondary publication: This article was published in its entirety in Eur Heart J 2012; 33:666-674.

Idiomas
Revista Portuguesa de Cardiologia
Opções de artigo
Ferramentas
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Ao assinalar que é «Profissional de Saúde», declara conhecer e aceitar que a responsável pelo tratamento dos dados pessoais dos utilizadores da página de internet da Revista Portuguesa de Cardiologia (RPC), é esta entidade, com sede no Campo Grande, n.º 28, 13.º, 1700-093 Lisboa, com os telefones 217 970 685 e 217 817 630, fax 217 931 095 e com o endereço de correio eletrónico revista@spc.pt. Declaro para todos os fins, que assumo inteira responsabilidade pela veracidade e exatidão da afirmação aqui fornecida.